Work

Rational design of a parthenolide-based drug regimen that selectively eradicates acute myelogenous leukemia stem cells.

Year: 2016

Type: article

Abstract: VOLUME 291 (2016) PAGES 21984–22000 The University of Arkansas for Medical Sciences and Dr. Peter A. Crooks have financial interests in melampomagnolide B (MMB) and structurally related analogs discussed in this manuscript. These financial interests have been reviewed and approved in accordance with the university's conflict of interest policies.

Source: Journal of Biological Chemistry

DOI: 10.1074/jbc.a116.750653

Authors: Shanshan Pei, Mohammad Minhajuddin, Angelo D'Alessandro, Travis Nemkov, Brett M. Stevens, Biniam Adane, Nabilah Khan, Fred K. Hagen, Vinod K. Yadav, Subhajyoti De, John M. Ashton, Kirk C. Hansen, Jonathan A. Gutman, Daniel A. Pollyea, Peter A. Crooks, Clayton Smith, Craig T. Jordan

Language: English

Topic: Sesquiterpenes and Asteraceae Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,430

OpenAlex ID: W4233596026

FWCI: 0.485

Cites:

Cited by: 10

Related to: 10